Melanotan II — Research Notes
Melanotan II is a synthetic alpha-MSH analog studied for skin pigmentation, sexual function, and melanocortin receptor pharmacology. It is the precursor compound that led to the development of PT-141 (bremelanotide), which is FDA-approved for women's sexual dysfunction.
What it is
Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring peptide that acts on melanocortin receptors throughout the body. It was developed at the University of Arizona in the 1980s and 1990s as part of a research program examining superpotent melanotropic peptides. A pilot Phase I human study was published in 1996, establishing MT-II's tanning and other melanocortin-mediated effects in humans.[1]
Unlike alpha-MSH, MT-II is non-selective: it activates multiple melanocortin receptor subtypes (MC1R, MC3R, MC4R, and MC5R), which accounts for its broad range of observed effects across pigmentation, sexual function, appetite, and other systems. Its structural modification (a lactam bridge creating a cyclic form) confers significantly greater potency and metabolic stability than endogenous alpha-MSH. A related compound, bremelanotide (PT-141), is a metabolite of MT-II and is now FDA-approved for hypoactive sexual desire disorder (HSDD) in women.
What researchers study it for
- Skin pigmentation and tanning MT-II acts on MC1R receptors on melanocytes to stimulate eumelanin (dark pigment) production. In the original Phase I human study, subcutaneous doses produced measurable tanning in two of three participants within one week of dosing, without UV exposure.[1]
- Sexual function in males and females MT-II's activation of MC4R receptors in the central nervous system has been studied in connection with sexual arousal and erectile function. Research has examined it as a lead compound for understanding how the melanocortin system regulates sexual response in both sexes, work that eventually led to the clinical development of bremelanotide.[2]
- Appetite and food intake regulation MC3R and MC4R activation by MT-II has been studied in animal models examining feeding behavior and appetite suppression; the melanocortin system is known to interact with hypothalamic circuits regulating energy intake.
- Melanocortin receptor pharmacology Because MT-II activates multiple receptor subtypes with high potency, it is used as a reference tool compound in basic research studying how individual melanocortin receptors mediate specific effects, providing a framework for designing selective, receptor-specific compounds.
- Underground use patterns and safety signals MT-II has been sold illicitly online for tanning purposes for decades. A 2018 observational study surveyed online forum users to document use patterns, motivations, and safety concerns associated with self-administration of unregulated MT-II.[3]
Research context
MT-II has a well-documented early clinical research history that distinguishes it from many research peptides. The Phase I human trial published by Dorr et al. in 1996 established that subcutaneous MT-II produces measurable skin darkening in humans and also generated the first observations of spontaneous penile erections as an unexpected effect, prompting the subsequent line of sexual function research.[1] That sexual function research ultimately led to the development of bremelanotide (PT-141), which received FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women. A 2014 review summarized the clinical development arc from MT-I and MT-II through to bremelanotide, characterizing the data as warranting further investigation into how melanocortin receptor activation mediates sexual response in both sexes.[2]
The safety picture for MT-II in the research context is complicated by its widespread self-administration in unregulated settings. MT-II is not FDA-approved for any indication, and it activates multiple receptor subtypes simultaneously, a property that accounts for its side effect profile (nausea, facial flushing, spontaneous erection, and yawning are commonly reported). There are also documented concerns about unregulated use contributing to changes in melanocytic nevi (moles). An observational study of online forum users found MT-II widely used for cosmetic tanning purposes, often outside any clinical oversight.[3] Researchers studying MT-II in controlled settings use it primarily as a pharmacological tool, not as a therapeutic candidate in its current non-selective form.
Typical research parameters
| Parameter | Typical range |
|---|---|
| Common vial sizes | 5 mg, 10 mg |
| Supplied as | Lyophilized powder, reconstituted with bacteriostatic water before use |
| Storage | Refrigerated after reconstitution; lyophilized powder stable at room temperature |
| Stability | Lyophilized: 24+ months / Reconstituted: 4–6 weeks refrigerated |
| Administration studied | Subcutaneous injection in human and animal research; intranasal formulations also studied |
References
- [1] Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences. 1996;58(20):1777–1784. PubMed ↗
- [2] Ückert S, Bannowsky A, Albrecht K, Kuczyk MA. Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies. Expert Opinion on Investigational Drugs. 2014;23(11):1477–1483. PubMed ↗
- [3] Callaghan DJ III. A glimpse into the underground market of melanotan. Dermatology Online Journal. 2018;24(5). PubMed ↗